SOLICITATION NOTICE
65 -- Thuramed TETRAS Peptide Synthesizer
- Notice Date
- 3/16/2010
- Notice Type
- Presolicitation
- NAICS
- 339112
— Surgical and Medical Instrument Manufacturing
- Contracting Office
- Department of Health and Human Services, National Institutes of Health, National Cancer Institute, Office of Acquisitions, 6120 Executive Blvd., EPS Suite 600, Rockville, Maryland, 20852
- ZIP Code
- 20852
- Solicitation Number
- NCI-100063-MM
- Archive Date
- 4/15/2010
- Point of Contact
- Melissa P Marino, Phone: 301-402-4509, Caren N Rasmussen, Phone: (301) 402-4509
- E-Mail Address
-
marinome@mail.nih.gov, cr214i@nih.gov
(marinome@mail.nih.gov, cr214i@nih.gov)
- Small Business Set-Aside
- N/A
- Description
- Contracting Office Address Department of Health and Human Services, National Institutes of Health, National Cancer Institute, Office of Acquisitions, 6120 Executive Boulevard, EPS Suite 600, Room 6072, Rockville, MD 20852, UNITED STATES. Description The National Cancer Institute (NCI), plans to procure on a sole source basis with CreoSalus Inc., 5609 Fern Valley Rd., Louisville, KY 40228 for the brand name Thuramed TETRAS Peptide Synthesizer. This acquisition will be processed in accordance with simplified acquisition procedures as stated in FAR Part 13.106-1(b)(1). Only one award will be made as a result of this solicitation. This will be awarded as a firm fixed price type contract. The Metabolism Branch supports an ongoing study of identifying molecular targets and pathways in malignancies and in identifying, isolating and testing new small peptide molecules for the potential treatment of cancers. An important approach in these efforts is to synthesize peptide-based molecules simultaneously. Manual solid phase peptide synthesis is extremely time-consuming both in the amount of reagents used and in the manpower necessary to produce hundreds of compounds. The use of an automated liquid handler such as a parallel peptide synthesizer greatly expedites the synthetic procedures minimizing human error and waste of valuable reagents. Facts and Reasons to Justify Other than Full and Open Competition: 1.Statutory authority: Statute: This justification has been prepared under the authority of 41 U.S.C. 253 (c)(1) as set forth in 13.106-1 (b)(1). (b) Soliciting from a single source. (1) For purchases not exceeding the simplified acquisition threshold, contracting officers may solicit from one source if the contracting officer determines that the circumstances of the contract action deem only one source reasonably available (e.g., urgency, exclusive licensing agreements, or industrial mobilization). No other requirement and/or type for supply or service will satisfy agency need. CreoSalus Inc., is uniquely qualified to provide a Thuramed TETRAS as it is the only known manufacturer to provide the ability to synthesize multiple peptides concurrently and asynchronously. The latter feature greatly reduces the time necessary to produce hundreds of molecules, effectively eliminating wait times. A major advantage unique to this system is the ability to perform organic synthesis reactions that are not limited to peptide synthesis. This is especially useful in the construction of compounds with different modifications aimed at the modulation of biological activity. Additionally, this is the only known instrument available that allows for around-the-clock remote monitoring of the syntheses. Current related data acquisition and analysis is being performed using a CreoSalus Thuramed TETRAS and switching vendors would put the continuity of research at risk as results from another source could be more difficult to interpret in relation to the current results. CreoSalus is also is uniquely qualified to provide rapid peptide synthesizer service because the Metabolism Branch collaborates with the laboratory at NIDDK which uses the Thuramed Tetras Peptide Synthesizer and the interchange of vials, tubing and software compatibility is important to the research efforts investigating protein-drug interactions. The synthesizer must be obtained from CreoSalus as similar instruments cannot meet the technical, safety or service that has been demonstrated and currently offered by CreoSalus. It is paramount that this research project's results be scientifically sound and therefore capable of withstanding the greatest amount of scientific question and scrutiny. In order to ensure the consistency and scientific merit of the experiments it is necessary that they be performed by the same instrument as ongoing experiments. For these reasons it was determined that this Thuramed Tetras system is the only qualified source for providing the required instrument. The salient characteristics of the Thuramed TETRAS peptide synthesizer are as follows: •Capacity for 106 concurrent 7ml reactions •Capacity for 20 concurrent 80ml reactions •Indexed Rotary Platform •Digital Servo Pumps for fluid delivery •Asynchronous synthesis software •Full networking capability •Concurrent variable scale synthesis •Fully independent reaction vessels •Online cleavage into individual vessels without disturbing other reactions •Remote alert notification •Modular construction •Reagent stations dedicated to each single reagent. •4 strategically placed purge stations for reaction vessel evacuation •Fully expandable by addition of reagent stations •All reagent stations capable of external line reagent source •1-32 pumped reagent stations •Sequence importation •Automatic protocol application •Software that calculates volume and dry weight of chemicals needed •Independent reaction vessel processing •Manual control over each reaction vessel •Integrated computer with Windows XP •Remote maintenance capabilities •36 total stations •Bench top unit •360 degree internal access and visibility •Self enclosed This is not a solicitation for competitive quotations. However, if any interested party believes they can meet the above requirement, they may submit a statement of capabilities. All information furnished must be in writing and must contain sufficient detail to allow the NCI to determine if it can meet the above unique specifications described herein. An original and one copy of the capability statement must be received in the NCI Office of Acquisitions on or before 11:00 AM EST on March 31, 2010. No electronic capability statements will be accepted (i.e. email or fax). An original and one copy must be sent to the NCI Office of Acquisitions at the address stated above. All questions must be in writing and can be faxed (301) 402-4513 or emailed to Melissa Marino, Contract Specialist, at marinome@mail.nih.gov. A determination by the Government not to compete this proposed contract based upon responses to this notice is solely within the discretion of the Government. Information received will be considered solely for the purpose of determining whether to conduct a competitive procurement. In order to receive an award, contractors must have valid registration and certification in the Central Contractor Registration (CCR) www.ccr.gov and the Online Representations and Certifications Applications (ORCA), http://orca.bpn.gov. No collect calls will be accepted. Please reference solicitation number NCI-100063-MM on all correspondence.
- Web Link
-
FBO.gov Permalink
(https://www.fbo.gov/spg/HHS/NIH/RCB/NCI-100063-MM/listing.html)
- Record
- SN02093863-W 20100318/100316235532-8a2e64c66f29aef55d5208e347c3e47c (fbodaily.com)
- Source
-
FedBizOpps Link to This Notice
(may not be valid after Archive Date)
| FSG Index | This Issue's Index | Today's FBO Daily Index Page |